By Jeff Montgomery ( August 23, 2018, 8:24 PM EDT) -- A Delaware vice chancellor warned Thursday that he saw no obvious winner in a battle over Fresenius Kabi AG's bid to walk away from a $4.3 billion deal to buy generic-drug maker Akorn Inc., with both sides accusing the other of fatal breaches during post-trial arguments....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.